NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

VINC

Vincerx Pharma Inc

Apr 25 • 03:56PM ET

0.0550

Dollar change -0.0126
Percentage change -18.64	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN GILD BMY AMGN VRTX BMRN EXEL INCY BLUE ALNY

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-15.85	Insider Own	4.11%	Shs Outstand	5.23M	Perf Week	-80.00%
Market Cap	0.29M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.94M	Perf Month	-90.19%
Income	-	PEG	-	EPS next Q	-	Inst Own	4.06%	Short Float	2.78%	Perf Quarter	-97.53%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.10	Perf Half Y	-99.28%
Book/sh	1.22	P/B	0.05	EPS next Y	-	ROA	-	Short Interest	0.14M	Perf Year	-99.68%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.05 - 18.70	Perf YTD	-98.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-99.71%	Beta	1.61
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	22.22%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	48.17%	Oper. Margin	-	RSI (14)	18.03	Volatility	93.44% 33.83%
Employees	12	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.32	Prev Close	0.07
Sales Surprise	-	EPS Surprise	21.54%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	1.31M	Price	0.05
SMA20	-85.53%	SMA50	-92.43%	SMA200	-99.18%	Trades		Volume	413,419	Change	-18.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-14-22	Initiated	H.C. Wainwright	Buy	$25
Dec-23-21	Initiated	Cantor Fitzgerald	Overweight	$25
Nov-01-21	Initiated	SVB Leerink	Outperform	$24
Sep-13-21	Initiated	Laidlaw	Buy	$30
Aug-25-21	Initiated	B. Riley Securities	Buy	$26

Apr-17-25 04:45PM	Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC (GlobeNewswire)
Apr-08-25 04:05PM	Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities (GlobeNewswire) -7.95% -49.24%
Mar-18-25 08:52AM	Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI (GlobeNewswire) -13.26%
Feb-28-25 04:05PM	Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives (GlobeNewswire) -13.49% -30.27%
Jan-29-25 08:00AM	Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's TROP2 Antibody Drug Conjugate, OQY-3258 (GlobeNewswire) -5.45%
04:05PM	Loading…
Jan-23-25 04:05PM	Vincerx Pharma, Inc. Announces Reverse Stock Split (GlobeNewswire) +15.89% -19.44%
Dec-27-24 04:05PM	Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. (GlobeNewswire) +5.49% +67.53%
Dec-05-24 06:50AM	Vincerx Pharma announces workforce reduction of 55%, cost-control measures (TipRanks) -12.88%
Dec-04-24 06:45AM	Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 (GlobeNewswire) -6.54%
Nov-12-24 09:00AM	Vincerx Pharma Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-10-24 12:00PM	What Makes Vincerx Pharma (VINC) a New Buy Stock (Zacks)
Oct-07-24 04:05PM	Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates (GlobeNewswire) -41.62%
Aug-08-24 04:30PM	Vincerx Pharma Reports Second Quarter 2024 Financial Results (GlobeNewswire) -7.55%
Jun-29-24 08:50PM	Why Is Applied Therapeutics, Inc. (APLT) the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
08:45PM	Loading…
08:45PM	C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
08:43PM	Why Did Analysts Give Alector, Inc. (ALEC) a Moderate Buy Rating? (Insider Monkey)
08:40PM	Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now? (Insider Monkey)
08:37PM	Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts? (Insider Monkey)
08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
08:32PM	Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating? (Insider Monkey)
08:28PM	Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now? (Insider Monkey)
08:26PM	Vigil Neuroscience, Inc. (VIGL): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-27-24 12:00PM	Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade (Zacks) +25.42%
May-14-24 09:54PM	VINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024 (InvestorPlace)
04:15PM	Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-24 06:35AM	Vincerx Pharma Prices Public Offering of Shares, Warrants (MT Newswires) -18.59%
12:27AM	Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants (GlobeNewswire)
Apr-25-24 04:01PM	Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants (GlobeNewswire)
01:34PM	Loading…
Apr-09-24 01:34PM	Vincerx (VINC) Tumbles on Results From Cancer Therapy Study (Zacks) -77.82%
12:29PM	Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday? (Benzinga)
08:40AM	Why Is Vincerx Pharma (VINC) Stock Down 64% Today? (InvestorPlace)
Apr-08-24 04:30PM	Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) -13.87%
Apr-02-24 07:53AM	VINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023 (InvestorPlace) +8.89%
Apr-01-24 08:00AM	Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +15.61%
Mar-29-24 04:51PM	Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look (GuruFocus.com)
03:20PM	Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Mar-14-24 09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey) -10.19%
Mar-05-24 04:31PM	Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +6.76% +27.12%
Jan-07-24 03:00PM	Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma (GlobeNewswire)
Dec-10-23 12:00PM	Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 (GlobeNewswire)
Nov-14-23 07:00AM	Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.99%
Nov-02-23 09:10AM	Vincerx Pharma To Present Three Posters at ASH 2023 in December (GlobeNewswire)
Oct-13-23 09:12AM	New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network (GlobeNewswire) +6.59%
Oct-06-23 09:30AM	New to The Street Announces TV Corporate Appearances, Broadcasting Episode 518 on Newsmax and Episode 519 on FOX Business Network, Airings start on Saturday, October 7, 2023, at 3:30 PM ET (GlobeNewswire)
Sep-19-23 07:00AM	Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Sep-14-23 07:00AM	Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 (GlobeNewswire) +6.43%
Aug-22-23 07:30AM	Vincerx Pharma Announces FDA Clearance of IND for VIP943 (GlobeNewswire) +6.94%
Aug-07-23 09:25AM	Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-23 04:05PM	Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +8.50%
Apr-19-23 09:05AM	Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-17-23 01:35PM	Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
08:00AM	Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-28-23 04:05PM	Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) +7.37%
Mar-14-23 04:35PM	Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
Feb-06-23 08:00AM	Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-13-22 09:29AM	Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its V3 Small Molecule-Drug Conjugate (SMDC) VIP236 (GlobeNewswire) +58.82%
Dec-12-22 04:05PM	Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types (GlobeNewswire) +5.67%
Dec-11-22 10:05AM	Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022 (GlobeNewswire)
Nov-10-22 04:05PM	Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) -10.22%
Nov-03-22 09:05AM	Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022 (GlobeNewswire)
Aug-11-22 04:05PM	Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) +8.82% +6.76%
09:43AM	We Think Vincerx Pharma (NASDAQ:VINC) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jul-01-22 06:03AM	Insider Buying: The Vincerx Pharma, Inc. (NASDAQ:VINC) Founder Just Bought 2.5% More Shares (Simply Wall St.) +6.06%
Jun-10-22 08:00AM	Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress (GlobeNewswire) -6.91%
Jun-07-22 02:11PM	Analysts Cuts Price Target On This Small Cap But Remain Bullish (Benzinga) +7.65%
08:25AM	Small Cap Biotech Vincerx Cuts Third Of Staff (Benzinga)
Jun-06-22 04:05PM	Vincerx Pharma Provides Key Strategic Update (GlobeNewswire)
06:24AM	Vincerx Pharma, Inc. (NASDAQ:VINC) up 10%, but insiders are still down 85% after purchasing US$806k of stock last year (Simply Wall St.)
May-12-22 04:05PM	Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) -10.20% -6.11%
Apr-08-22 01:05PM	Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) -5.76%
Mar-29-22 08:00AM	Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-08-22 04:35PM	Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) +5.26%
Feb-09-22 08:00AM	Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire)
Feb-03-22 08:30AM	Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers (GlobeNewswire) -5.36%
Jan-30-22 06:32PM	2 Strong Buy Stocks Under $10 With Over 100% Upside Potential (TipRanks)
Dec-28-21 09:35AM	Vincerx Pharma, Inc. (NASDAQ:VINC) insiders placed bullish bets worth US$741k in the last 12 months (Simply Wall St.) +5.09%
Dec-17-21 08:00AM	Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome (GlobeNewswire)
Dec-11-21 03:30PM	Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-07-21 08:00AM	Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma (GlobeNewswire) +8.90%
Dec-06-21 08:00AM	Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data Presented at the American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-12-21 08:00AM	Vincerx Pharma Reports Third Quarter 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-21 09:01AM	Vincerx Pharma Announces Presentations at the American Society of Hematology Annual Meeting (GlobeNewswire)
Sep-16-21 07:30AM	Vincerx Pharma Announces $50 Million Private Placement (GlobeNewswire)
Sep-07-21 08:00AM	Vincerx Pharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference (GlobeNewswire)
Aug-12-21 04:05PM	Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update (GlobeNewswire) +10.49%
Jul-30-21 09:55AM	Is Vincerx Pharma, Inc. (VINC) A Good Stock To Buy? (Insider Monkey) -5.15%
Jul-01-21 02:42AM	Insider Buying: The Vincerx Pharma, Inc. (NASDAQ:VINC) Independent Director Just Bought US$126k Worth Of Shares (Simply Wall St.) +17.71%
Jun-28-21 08:00AM	Vincerx Pharma Announces Inclusion in Russell 3000® and Microcap® Indexes (GlobeNewswire)
Jun-04-21 12:40PM	UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021 (GlobeNewswire)
08:00AM	Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021 (GlobeNewswire)
Jun-03-21 04:05PM	Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors (GlobeNewswire)
May-26-21 08:00AM	Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-17-21 08:00AM	Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-06-21 08:00AM	Vincerx Pharma Announces Completion of Public Warrant Redemption (GlobeNewswire)
Apr-20-21 08:00AM	Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome (GlobeNewswire)
Apr-10-21 08:31AM	Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021 (GlobeNewswire)
Apr-07-21 08:00AM	Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors (GlobeNewswire)
Apr-05-21 08:00AM	Vincerx Pharma Announces Redemption of Public Warrants (GlobeNewswire)

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop ADCs and SMDCs; and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory AML, higher-risk MDS, and B-ALL; VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies; VIP236, a small molecule-drug conjugate, which is in Phase 1 dose-escalation study in patients with advanced or metastatic solid tumors; and Enitociclib, a highly selective CDK9 inhibitor, which is in Phase 1 clinical trial. Vincerx Pharma, Inc. was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. The company was founded in 2019 and is based in San Mateo, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VINC

Vincerx Pharma Inc

Upgrade your FINVIZ experience